Welcome to BioSeeker Group!

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

Additional Information

Published Date Aug 25, 2009
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 767
PDF Fact Sheet View Fact Sheet for the report Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning.

    To find out more about Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting lung cancer sub-indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 18
4.2 List of Tables 19
5 Introduction 27
5.1 The Scope of this Report 27
5.2 Definitions 30
5.3 Abbreviations 30
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 31
6.1 Drug Repositioning in Oncology 31
6.2 Introduction to Lung Cancer Drug Targets 32
6.2.1 Carboxy-lyase Activity Targets 34
6.2.2 Catalytic ActivityTargets 35
6.2.3 Cell Adhesion Molecule Activity Targets 37
6.2.4 Chaperone ActivityTargets 43
6.2.5 Chemokine Activity Targets 46
6.2.6 Complement Activity Targets 48
6.2.7 Cysteine-Type Peptidase Activity Targets 49
6.2.8 Cytokine Activity Targets 54
6.2.9 DNA Binding Targets 60
6.2.10 DNA Repair Protein Targets 61
6.2.11 DNA Topoisomerase Activity Targets 63
6.2.12 DNA-Directed DNA Polymerase Activity Targets 67
6.2.13 DNA-methyltransferase Activity Targets 73
6.2.14 Extracellular Ligand-Gated Ion Channel Activity Targets 74
6.2.15 Extracellular Matrix Structural Constituent Targets 75
6.2.16 G-protein Coupled Receptor Activity Targets 76
6.2.17 Glutathione Transferase Activity Targets 81
6.2.18 Growth Factor Activity Targets 82
6.2.19 GTPase Activity Targets 85
6.2.20 Hormone activity Targets 92
6.2.21 Hydrolase Activity Targets 93
6.2.22 Ion channel Activity Targets 94
6.2.23 Kinase Activity Targets 95
6.2.24 Kinase regulator activity Targets 101
6.2.25 Ligase Activity Targets 102
6.2.26 Lipase Activity Targets 105
6.2.27 Lipid Kinase Activity Targets 106
6.2.28 Metallopeptidase Activity Targets 107
6.2.29 Molecular Function Unknown Targets 110
6.2.30 Motor Activity Targets 116
6.2.31 Oxidoreductase Activity Targets 117
6.2.32 Peptidase Activity Targets 120
6.2.33 Peroxidase Activity Targets 122
6.2.34 Phosphoric Diester Hydrolase Activity Targets 123
6.2.35 Protein binding Targets 125
6.2.36 Protein Serine/Threonine Kinase Activity Targets 126
6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets 142
6.2.38 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 145
6.2.39 Protein-Tyrosine Kinase Activity Targets 146
6.2.40 Receptor Activity Targets 156
6.2.41 Receptor binding Targets 167
6.2.42 Receptor Signaling Complex Scaffold Activity Targets 170
6.2.43 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 173
6.2.44 RNA Binding Targets 174
6.2.45 RNA-Directed DNA Polymerase Activity Targets 175
6.2.46 Serine-Type Peptidase Activity Targets 176
6.2.47 Structural Constituent of Cytoskeleton Targets 179
6.2.48 Transcription Factor Activity Targets 181
6.2.49 Transcription Regulator Activity Targets 195
6.2.50 Transcription Regulator Activity Targets 200
6.2.51 Transferase Activity Targets 201
6.2.52 Transmembrane Receptor Activity Targets 203
6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 205
6.2.54 Transporter Activity Targets 241
6.2.55 Ubiquitin-Specific Protease Activity Targets 246
6.2.56 Other Targets 247
6.3 The Cancer Genome Project and Lung Cancer Targets 248
6.3.1 Lung Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 248
6.4 Structure-based Drug Design in Lung Cancer is Stimulated by Available Structure Data on Biological Targets 252
6.5 Target-Target Interactions among Identified Lung Cancer Targets 256
6.6 The Drug-Target Interactome 261
6.7 Protein Expression Levels of Identified Drug Targets of Lung Cancer Drugs 266
6.8 Pathway Analysis of Lung Cancer Drug Targets 274
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? 324
7.1 Terminated Drug Target Profiles in Lung Cancer 327
7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 330
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 331
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lung Cancer Pipeline 333
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 338
7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 342
7.7 Development Profiles of All Lung Cancer Drug Target Profiles 344
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound 369
8.1 Small Molecules 371
8.1.1 Background 371
8.1.2 Targets in Lung Cancer 372
8.2 Peptide/Protein Drugs 386
8.2.1 Background 386
8.2.2 Targets in Lung Cancer 387
8.3 Antibodies and Antibody-like Structures 391
8.3.1 Background 391
8.3.2 Targets in Lung Cancer 391
8.4 Nucleic Acid Therapies 395
8.4.1 Background 395
8.4.2 Targets in Lung Cancer 396
8.5 Gene Therapy 398
8.5.1 Background 398
8.5.2 Targets in Lung Cancer 398
8.6 Drug Delivery and Nanotechnology 401
8.6.1 Background 401
8.6.2 Targets in Lung Cancer 401
8.7 The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer 404
8.8 Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 411
9 Selecting a Sub-Indication of Lung Cancer for Drug Development 420
9.1 Lung Cancer (general) 421
9.1.1 Players and their Compared Pipeline 421
9.1.2 Where is the Real Competition? 426
9.1.3 How Successful are They in Their Targeting Strategy? 428
9.2 Non-Small Cell Lung Cancer 430
9.2.1 Players and their Compared Pipeline 430
9.2.2 Where is the Real Competition? 442
9.2.3 How Successful are They in Their Targeting Strategy? 446
9.3 Small Cell Lung Cancer 455
9.3.1 Players and their Compared Pipeline 455
9.3.2 Where is the Real Competition? 460
9.3.3 How Successful are They in Their Targeting Strategy? 461
10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator 463
10.1 Abbott 465
10.2 Abraxis BioScience 468
10.3 Active Biotech 470
10.4 Adherex 471
10.5 Advantagene 472
10.6 AEgera 473
10.7 Aeterna Zentaris 474
10.8 Agennix 476
10.9 Aida Pharmaceuticals 477
10.10 Alchemia 478
10.11 Alethia Biotherapeutics 480
10.12 Allos Therapeutics 481
10.13 Amgen 482
10.14 Antisense Pharma 485
10.15 Antisoma 486
10.16 Anza Therapeutics 487
10.17 ApopLogic Pharmaceuticals 488
10.18 Archer Biosciences 490
10.19 Ariad 492
10.20 ArQule 494
10.21 Array BioPharma 496
10.22 Ascenta Therapeutics 497
10.23 Astellas 498
10.24 AstraZeneca 499
10.25 Bayer 502
10.26 Biogen Idec 505
10.27 Biokine Therapeutics 507
10.28 BioNumerik 508
10.29 Boehringer Ingelheim 510
10.30 Bristol-Myers Squibb 512
10.31 BTG 519
10.32 CanBas 521
10.33 Celator Pharmaceuticals 522
10.34 Cell Genesys 524
10.35 Cell Therapeutics 525
10.36 Celtic Pharma 528
10.37 Center of Molecular Immunology 529
10.38 Cephalon 531
10.39 CG Therapeutics 532
10.40 Chemokine Therapeutics 533
10.41 Chong Kun Dang 534
10.42 Clavis Pharma 536
10.43 CLL Pharma 537
10.44 Critical Outcome Technologies 539
10.45 Cyclacel 540
10.46 CytImmune Sciences 541
10.47 Cytokinetics 542
10.48 Dabur Pharma 543
10.49 Daiichi Sankyo 545
10.50 Dainippon Sumitomo Pharma 548
10.51 Dara Biosciences 550
10.52 Dendreon 551
10.53 Dong-A 553
10.54 Eisai 555
10.55 Eli Lilly 557
10.56 Endocyte 560
10.57 EntreMed 561
10.58 EpiCept 562
10.59 Exelixis 564
10.60 Galapagos 568
10.61 Gemin X Pharmaceuticals 569
10.62 Genentech 570
10.63 Genmab 573
10.64 Genta 575
10.65 GenVec 577
10.66 Genzyme 578
10.67 Geron 579
10.68 GlaxoSmithKline 580
10.69 GlobeImmune 584
10.70 GlycoGenesys 585
10.71 Hana Biosciences 586
10.72 Hoffmann-La Roche 587
10.73 Human Genome Sciences 588
10.74 Idera Pharmaceuticals 589
10.75 ImClone Systems 590
10.76 ImmunoCellular Therapeutics 593
10.77 Immunocore 594
10.78 ImmunoGen 596
10.79 Immunomedics 598
10.80 Incyte Corporation 601
10.81 Infinity Pharmaceuticals 602
10.82 Innovive 603
10.83 Inovio 605
10.84 Introgen Therapeutics 606
10.85 Ipsen 608
10.86 Isis Pharmaceuticals 610
10.87 Jennerex Biotherapeutics 611
10.88 Johnson & Johnson 612
10.89 Kiadis 615
10.90 Kyowa Hakko Kirin 617
10.91 Lorus Therapeutics 620
10.92 MacroGenics 621
10.93 Medarex 622
10.94 MediGene 624
10.95 Medisyn Technologies 625
10.96 Menarini 627
10.97 Merck KGaA 629
10.98 MethylGene 632
10.99 Micromet 634
10.100 Mirna Therapeutics 636
10.101 MolMed 637
10.102 Mologen 638
10.103 Nektar Therapeutics 639
10.104 NeoPharm 641
10.105 Nerviano Medical Sciences 644
10.106 Novacea 646
10.107 Novartis 647
10.108 OncoGenex Pharmaceuticals 652
10.109 Oncothyreon 655
10.110 OSI Pharmaceuticals 656
10.111 OXiGENE 660
10.112 PanaGin 661
10.113 PBL Therapeutics 662
10.114 PDL BioPharma 663
10.115 Pfizer 664
10.116 Pharmacyclics 669
10.117 PharmaGap 670
10.118 PharmaMar 671
10.119 Pharmexa 674
10.120 Pierre Fabre 676
10.121 Pro-Pharmaceuticals 677
10.122 Progen 678
10.123 Protox Therapeutics 679
10.124 Receptor BioLogix 680
10.125 Regulon 682
10.126 RESprotect 683
10.127 Samyang 684
10.128 Sanofi-Aventis 687
10.129 Sareum 690
10.130 Schering-Plough 692
10.131 Seattle Genetics 693
10.132 ShimodaAtlantic Oncology 694
10.133 Shire 695
10.134 Sigma-Tau 696
10.135 Simcere Pharmaceuticals 698
10.136 SRI International 699
10.137 SuperGen 700
10.138 Supratek Pharma 703
10.139 Switch Pharma 706
10.140 Taiho 707
10.141 Takeda 709
10.142 Taxolog 711
10.143 Tekmira Pharmaceuticals 714
10.144 Telik 716
10.145 Thallion Pharmaceuticals 717
10.146 Therion Biologics 719
10.147 Titan Pharmaceuticals 720
10.148 Tracon Pharmaceuticals 722
10.149 Tragara Pharmaceuticals 723
10.150 Transgene 724
10.151 Trion Pharma 726
10.152 Twinstrand Therapeutics 727
10.153 UCB 728
10.154 Valeant 730
10.155 Vaxon Biotech 731
10.156 Vertex Pharmaceuticals 732
10.157 Vion Pharmaceuticals 733
10.158 ViRexx 735
10.159 Voyager Pharmaceutical 736
10.160 Wilex 737
10.161 Wyeth 738
10.162 Xerion 742
10.163 Xoma 744
10.164 Yakult Honsha 745
10.165 YM BioSciences 747
10.166 Zivena 749
10.167 Non-industrial Organizations 751
11 Disclaimer 752
12 Drug Index 753
13 Company Index 761

4.1 List of Figures
Figure 1: Overall Breakdown of the Included Lung Cancer Therapeutic Pipeline by Sub-Indication and Stage of Development 27
Figure 2: Visualization of Target-Target Interactions Among Lung Cancer Drug Targets 260
Figure 3: The Drug-Protein Interactome of Lung Cancer Drugs –Clusters I 263
Figure 4: The Drug-Protein Interactome of Lung Cancer Drugs – Clusters II 264
Figure 5: Head-to-Head Targeting Interactome of Lung Cancer Drugs 265
Figure 6: Distribution of Compound Types among Lung Cancer Drugs 411
Figure 7: Primary Sub-cellular Localization of Drug Targets 412
Figure 8: Breakdown of the Lung Cancer (general) Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development 424
Figure 9: Compound Strategy Breakdown of the Lung Cancer (general) Pipeline 425
Figure 10: Breakdown of the Non-Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development 439
Figure 11: Compound Strategy Breakdown of the Non-Small Cell Lung Cancer Pipeline 441
Figure 12: Breakdown of the Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development 458
Figure 13: Compound Strategy Breakdown of the Small Cell Lung Cancer Pipeline 459

4.2 List of Tables
Table 1: Competitive Pressure Force Among Lung Cancer Drugs 26
Table 2: Overview of Drug Target Profile Themes 31
Table 3: Terminally Ceased Therapeutic Lung Cancer Targets 32
Table 4: Drug Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 248
Table 5: Identity of Lung Cancer Drug Targets with Available Biological Structures 252
Table 6: Number of Target-Target Interactions among Lung Cancer Drug Targets 255
Table 7: Drug-Protein Interactome Clusters 260
Table 8: Lung Cancer Drug Targets with Available Protein Expression Profiles 265
Table 9: Expression Levels of Identified Drug Targets in Lung Cancer Tissue 269
Table 10: Pathway Summary 273
Table 11: Drug Targets without any Identified Assigned Pathways 273
Table 12: Pathway Profile According to BioCarta of Lung Cancer Drug Targets 274
Table 13: Pathway Profile According to KEGG of Lung Cancer Drug Targets 297
Table 14: Pathway Profile According to NetPath of Lung Cancer Drug Targets 318
Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 323
Table 16: Top Competitive Lung Cancer Target Profiles 324
Table 17: Terminated Drug Target Strategies in Lung Cancer 326
Table 18 New and Unique Lung Cancer Target Strategies in Pre-Registration to Marketed 329
Table 19: New and Unique Lung Cancer Target Strategies in Phase III Clinical Development 330
Table 20: New and Unique Lung Cancer Target Strategies in Phase II Clinical Development 332
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs 335
Table 22 New and Unique Lung Cancer Target Strategies in Phase I Clinical Development 337
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs 339
Table 24: New and Unique Lung Cancer Target Strategies in Preclinical Development 341
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs 342
Table 26: The Progression, Maturity and Competitive Comparison of Lung Cancer Drug Target Profiles in Development 343
Table 27: Overview of Compound Strategy Competition in Lung Cancer 369
Table 28:Overview of the Competitive Landscape of Small Molecular Drugs in Lung Cancer 371
Table 29: Head-to-Head Target Competition Between Small Molecule Drugs for the Treatment of Lung Cancer 372
Table 30: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lung Cancer 373
Table 31: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Lung Cancer Drugs in Development 376
Table 32: Overview of the Competitive Landscape of Peptide Based Drugs in Lung Cancer 386
Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Lung Cancer Drug in Development 386
Table 34:Overview of the Competitive Landscape of Protein Based Drugs in Lung Cancer 387
Table 35: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lung Cancer 388
Table 36: The Progression, Maturity and Competitive Comparison of Protein Based Lung Cancer Drug Target Profiles in Development 388
Table 37:Overview of the Competitive Landscape of Antibody Drugs in Lung Cancer 390
Table 38: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lung Cancer 391
Table 39: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Lung Cancer Drugs in Development 392
Table 40:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lung Cancer 395
Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Lung Cancer Drugs in Development 395
Table 42: Vectors in Gene Therapy 397
Table 43:Overview of the Competitive Landscape of Gene Therapy Drugs in Lung Cancer 397
Table 44: The Competition Through Close Mechanistic Approximation Between Gene Therapy Drugs in Lung Cancer 398
Table 45: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Lung Cancer Drugs in Development 398
Table 46:Overview of the Competitive Landscape of Reformulated Drugs in Lung Cancer 400
Table 47: The Competition Through Close Mechanistic Approximation Between Reformulated Drugs in Lung Cancer 401
Table 48: The Progression, Maturity and Competitive Comparison of Target Profiles of Reformulated Lung Cancer Drugs in Development 401
Table 49: The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer 403
Table 50: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 411
Table 51: Competitive Summary of Lung Cancer Drugs by Sub-Indication 419
Table 52: Players in the Field of Lung Cancer (general) Drug Development and their Compared Pipeline 420
Table 53: The Competition Through Close Mechanistic Approximation Between Lung Cancer (general) Drugs 425
Table 54: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lung Cancer (general) Drug Development 427
Table 55: Players in the Field of Non-Small Cell Lung Cancer Drug Development and their Compared Pipeline 429
Table 56: The Competition Through Close Mechanistic Approximation Between Non-Small Cell Lung Cancer Drugs 441
Table 57: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Small Cell Lung Cancer Drug Development 445
Table 58: Players in the Field of Small Cell Lung Cancer Drug Development and their Compared Pipeline 454
Table 59: The Competition Through Close Mechanistic Approximation Between Small Cell Lung Cancer Drugs 459
Table 60: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Small Cell Lung Cancer Drug Development 460
Table 61: Abbott’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 464
Table 62: Abraxis BioScience’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 467
Table 63: Active Biotech’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 469
Table 64: Adherex’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 470
Table 65: Advantagene’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 471
Table 66: AEgera’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 472
Table 67: Aeterna Zentaris’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 473
Table 68: Agennix’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 475
Table 69: Aida Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 476
Table 70: Alchemia’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 477
Table 71: Alethia Biotherapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 479
Table 72: Allos Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 480
Table 73: Amgen’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 481
Table 74: Antisense Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 484
Table 75: Antisoma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 485
Table 76: Anza Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 486
Table 77: ApopLogic Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 487
Table 78: Archer Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 489
Table 79: Ariad’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 491
Table 80: ArQule’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 493
Table 81: Array BioPharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 495
Table 82: Ascenta Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 496
Table 83: Astellas’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 497
Table 84: AstraZeneca’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 498
Table 85: Bayer’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 501
Table 86: Biogen Idec’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 504
Table 87: Biokine Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 506
Table 88: BioNumerik’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 507
Table 89: Boehringer Ingelheim’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 509
Table 90: Bristol-Myers Squibb’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 511
Table 91: BTG’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 518
Table 92: CanBas’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 520
Table 93: Celator Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 521
Table 94: Cell Genesys’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 523
Table 95: Cell Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 524
Table 96: Celtic Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 527
Table 97: Center of Molecular Immunology’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 528
Table 98: Cephalon’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 530
Table 99: CG Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 531
Table 100: Chemokine Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 532
Table 101: Chong Kun Dang’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 533
Table 102: Clavis Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 535
Table 103: CLL Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 536
Table 104: Critical Outcome Technologies’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 538
Table 105: Cyclacel’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 539
Table 106: CytImmune Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 540
Table 107: Cytokinetics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 541
Table 108: Dabur Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 542
Table 109: Daiichi Sankyo’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 544
Table 110: Dainippon Sumitomo Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 547
Table 111: Dara Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 549
Table 112: Dendreon’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 550
Table 113: Dong-A’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 552
Table 114: Eisai’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 554
Table 115: Eli Lilly’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 556
Table 116: Endocyte’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 559
Table 117: EntreMed’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 560
Table 118: EpiCept’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 561
Table 119: Exelixis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 563
Table 120: Galapagos’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 567
Table 121: Gemin X Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 568
Table 122: Genentech’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 569
Table 123: Genmab’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 572
Table 124: Genta’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 574
Table 125: GenVec’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 576
Table 126: Genzyme’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 577
Table 127: Geron’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 578
Table 128: GlaxoSmithKline’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 579
Table 129: GlobeImmune’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 583
Table 130: GlycoGenesys’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 584
Table 131: Hana Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 585
Table 132: Hoffmann-La Roche’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 586
Table 133: Human Genome Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 587
Table 134: Idera Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 588
Table 135: ImClone Systems’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 589
Table 136: ImmunoCellular Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 592
Table 137: Immunocore’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 593
Table 138: ImmunoGen’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 595
Table 139: Immunomedics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 597
Table 140: Incyte Corporation’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 600
Table 141: Infinity Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 601
Table 142: Innovive’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 602
Table 143: Inovio’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 604
Table 144: Introgen Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 605
Table 145: Ipsen’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 607
Table 146: Isis Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 609
Table 147: Jennerex Biotherapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 610
Table 148: Johnson & Johnson’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 611
Table 149: Kiadis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 614
Table 150: Kyowa Hakko Kirin’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 616
Table 151: Lorus Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 619
Table 152: MacroGenics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 620
Table 153: Medarex’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 621
Table 154: MediGene’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 623
Table 155: Medisyn Technologies’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 624
Table 156: Menarini’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 626
Table 157: Merck KGaA’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 628
Table 158: MethylGene’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 631
Table 159: Micromet’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 633
Table 160: Mirna Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 635
Table 161: MolMed’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 636
Table 162: Mologen’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 637
Table 163: Nektar Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 638
Table 164: NeoPharm’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 640
Table 165: Nerviano Medical Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 643
Table 166: Novacea’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 645
Table 167: Novartis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 646
Table 168: OncoGenex Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 651
Table 169: Oncothyreon’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 654
Table 170: OSI Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 655
Table 171: OXiGENE’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 659
Table 172: PanaGin’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 660
Table 173: PBL Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 661
Table 174: PDL BioPharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 662
Table 175: Pfizer’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 663
Table 176: Pharmacyclics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 668
Table 177: PharmaGap’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 669
Table 178: PharmaMar’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 670
Table 179: Pharmexa’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 673
Table 180: Pierre Fabre’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 675
Table 181: Pro-Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 676
Table 182: Progen’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 677
Table 183: Protox Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 678
Table 184: Receptor BioLogix’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 679
Table 185: Regulon’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 681
Table 186: RESprotect’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 682
Table 187: Samyang’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 683
Table 188: Sanofi-Aventis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 686
Table 189: Sareum’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 689
Table 190: Schering-Plough’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 691
Table 191: Seattle Genetics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 692
Table 192: ShimodaAtlantic Oncology’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 693
Table 193: Shire’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 694
Table 194: Sigma-Tau’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 695
Table 195: Simcere Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 697
Table 196: SRI International’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 698
Table 197: SuperGen’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 699
Table 198: Supratek Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 702
Table 199: Switch Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 705
Table 200: Taiho’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 706
Table 201: Takeda’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 708
Table 202: Taxolog’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 710
Table 203: Tekmira Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 713
Table 204: Telik’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 715
Table 205: Thallion Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 716
Table 206: Therion Biologics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 718
Table 207: Titan Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 719
Table 208: Tracon Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 721
Table 209: Tragara Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 722
Table 210: Transgene’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 723
Table 211: Trion Pharma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 725
Table 212: Twinstrand Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 726
Table 213: UCB’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 727
Table 214: Valeant’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 729
Table 215: Vaxon Biotech’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 730
Table 216: Vertex Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 731
Table 217: Vion Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 732
Table 218: ViRexx’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 734
Table 219: Voyager Pharmaceutical’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 735
Table 220: Wilex’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 736
Table 221: Wyeth’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 737
Table 222: Xerion’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 741
Table 223: Xoma’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 743
Table 224: Yakult Honsha’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 744
Table 225: YM BioSciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 746
Table 226: Zivena’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 748
Table 227: Non-industrial source’s Included Lung Cancer Pipeline Composition and Competitive Fall-Out 750

This analysis includes 167 investigators. In addition to these, drug development partners are also listed.
Abbott
Abraxis BioScience
Active Biotech
Adherex
Advantagene
AEgera
Aeterna Zentaris
Agennix
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Amgen
Antisense Pharma
Antisoma
Anza Therapeutics
ApopLogic Pharmaceuticals
Archer Biosciences
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
Bayer
Biogen Idec
Biokine Therapeutics
BioNumerik
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
CanBas
Celator Pharmaceuticals
Cell Genesys
Cell Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Clavis Pharma
CLL Pharma
Critical Outcome Technologies
Cyclacel
CytImmune Sciences
Cytokinetics
Dabur Pharma
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
Dong-A
Eisai
Eli Lilly
Endocyte
EntreMed
EpiCept
Exelixis
Galapagos
Gemin X Pharmaceuticals
Genentech
Genmab
Genta
GenVec
Genzyme
Geron
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Hana Biosciences
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Incyte Corporation
Infinity Pharmaceuticals
Innovive
Inovio
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kiadis
Kyowa Hakko Kirin
Lorus Therapeutics
MacroGenics
Medarex
MediGene
Medisyn Technologies
Menarini
Merck KGaA
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Nektar Therapeutics
NeoPharm
Nerviano Medical Sciences
Non-industrial source
Novacea
Novartis
OncoGenex Pharmaceuticals
Oncothyreon
OSI Pharmaceuticals
OXiGENE
PanaGin
PBL Therapeutics
PDL BioPharma
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pierre Fabre
Progen
Pro-Pharmaceuticals
Protox Therapeutics
Receptor BioLogix
Regulon
RESprotect
Samyang
Sanofi-Aventis
Sareum
Schering-Plough
Seattle Genetics
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Simcere Pharmaceuticals
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Taiho
Takeda
Taxolog
Tekmira Pharmaceuticals
Telik
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UCB
Valeant
Vaxon Biotech
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
ViRexx
Voyager Pharmaceutical
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zivena
This analysis includes 283 drugs. Example of drugs included are:
amrubicin hydrochloride
belotecan hydrochloride
bevacizumab
BIBW-2992
canfosfamide hydrochloride
cetuximab
CP-751871
docetaxel
endostatin
erlotinib
etoposide (1)
etoposide phosphate
gefitinib
GSK-1572932A
interferon (1)
irinotecan hydrochloride
lapatinib ditosylate
motesanib diphosphate
motexafin gadolinium
oblimersen sodium
paclitaxel (1)
paclitaxel (2)
paclitaxel (4)
paclitaxel (5)
paclitaxel (8)
paclitaxel polyglumex
pemetrexed disodium
PF-676
sorafenib tosylate
Stimuvax
sunitinib malate
tegafur + uracil
topotecan
TS-1
vandetanib

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning.
    To find out more about Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More


Melanoma - Targeted Therapeutics
This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. Learn More

Other selected research from the 'Oncology' category:


Calcium Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 276 companies plus partners who are today developing 335 calcium signaling pathway targeting drugs in 1110 developmental projects in cancer across 145 different targets. In addition, there is 1 suspended drug and another 130 drugs where development has been ceased. Learn More


Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Pancreatic Cancer. Learn More